title: [Impact of pathological review by an expert on the diagnosis and management of patients with cancer in Aquitania].
abstract: OBJECTIVE
  The goal of this work was to evaluate the impact of expert pathological second opinion on the diagnosis and management of patients with cancer, in a French region (Aquitaine) and with an economic point of view.
  
  
  METHODS
  The study was first quantitative, performed retrospectively on all cases of cancer, voluntary sent for a second opinion to an expert pathologist of two centers. Secondly, we restricted the study to lymphoid, melanocytic and soft tissue tumors sent for second opinion. We considered that the expert review had an important diagnostic impact either when the initial pathologist sent the specimen to identify or classify malignant tumor or hesitated between benign and malignant tumor or had no hypothesis, or if there were discordant diagnoses (malignant/benign) between the two pathologists. We considered that the expert review had a high therapeutic impact if the disagreement between initial and expert diagnoses induced a complete modification in therapy. We evaluated the cost of second opinion for the expert centers and the cost of care management.
  
  
  RESULTS
  Over the year 2006, the expert centers received 5077 lesions for consultation: 3769 specimens were sent by a pathologist for a second review, 1324 by pathologists of Aquitania and of these, 751 samples were submitted for lymphoid (55%), soft tissues (30%) or melanocytic tumors (15%). There was an important diagnostic impact for 75% of the samples; the impact of the expert review on patient management was considered high for 46% of specimens and the expert pathological diagnosis modified the clinical prognosis for 40% of the specimens. We estimated that for 53 discordant diagnoses (malignant/benign), second opinion allowed an economy of 500,000 euro.
  
  
  CONCLUSIONS
  Expert second opinion is very important not only for diagnosis and management for patient with cancer but also for economic reasons.
authors.affiliation: Réseau de cancérologie d'Aquitaine, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Nadège
authors.initials: N
authors.lastname: Lapeyrere
authors.forename: Marie
authors.initials: M
authors.lastname: Parrens
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Coindre
authors.forename: Isabelle
authors.initials: I
authors.lastname: Soubeyran
authors.forename: Antoine
authors.initials: A
authors.lastname: de Mascarel
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Merlio
authors.forename: Brigitte
authors.initials: B
authors.lastname: Lebail
authors.forename: Sébastien
authors.initials: S
authors.lastname: Lepreux
authors.forename: Anne
authors.initials: A
authors.lastname: Jaffre
authors.forename: Véronique
authors.initials: V
authors.lastname: Gilleron
authors.forename: Simone
authors.initials: S
authors.lastname: Mathoulin-Pélissier
authors.forename: Béatrice
authors.initials: B
authors.lastname: Vergier
mesh_terms: D017281:Cost of Illness; D003937:Diagnosis, Differential; D005104:Expert Testimony; D005602:France; D006801:Humans; D007150:Immunohistochemistry; D008223:Lymphoma / Q000473:pathology; D008545:Melanoma / Q000473:pathology; D009369:Neoplasms / Q000191:economics / Q000473:pathology*; D010336:Pathology / Q000592:standards; D012189:Retrospective Studies; D012509:Sarcoma / Q000473:pathology